Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cariprazine in Adolescents With Schizophrenia
2024-513194-44-00Phase 3Completed
- Sponsor
- Gedeon Richter Plc
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Cariprazine (Reagila) with Placebo (2 arms). Primary endpoint: Change from baseline to Week 6 on the PANSS total score. Started Jul 2024; status: completed.
02
Drugs
cariprazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2024-513194-44-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513194-44-00.